Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Tumor cells constitutively express indoleamine 2,3-dioxygenase (IDO), which degrades tryptophan and lowers tryptophan concentration in the local microenvironment. Such altered microenvironment protects tumor cells from rejection by the immune system, as T lymphocytes are exquisitely sensitive to tryptophan shortage. This may explain the low clinical efficacy of cancer immunotherapy based on vaccination. Preclinical studies indicate that this immune resistance mechanism can be blocked by systemic delivery of a pharmacological IDO inhibitor, 1-methyl-l-tryptophan. These results suggest the clinical efficacy of cancer immunotherapy can be boosted by combined treatment of cancer patients with an IDO inhibitor. © 2007 Elsevier B.V. All rights reserved.

Original publication

DOI

10.1016/j.ics.2007.07.043

Type

Journal article

Journal

International Congress Series

Publication Date

01/11/2007

Volume

1304

Pages

274 - 277